Revised Early Notification and Brand Change Compound Electrolytes
As advised via PHARMAC Tender Results of 31 May 2019 there is to be a change in the listing and future sole supply of Compound Electrolytes. (Refer to Mind Time article 5 July 2019)
New listing from 1 November 2019
Electral Powder for Oral Solution 50 sachet pack Pharmacode 2576937 Schedule price $9.77
Enerlyte Powder for oral Solution 10 sachet pack Pharmacode 2441292 Schedule price $2.30
HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 April 2020.
Brand switch fee for Community Pharmacy not notified with tender results.
As of the date of this notification ProPharma / PWR cannot accept Enerlyte Sachets for credit under any circumstances.
From 1 November 2019 community pharmacies dispensing Compound Electrolyte will need to support patients changing to the new brand and manage stock during the transition.
We would recommend you continue to purchase the incumbent product until stocks are depleted or 1 April 2020, whichever comes first.
There is a benefit in continuing to dispense the incumbent from a reimbursement point of view as follows:-
Enerlyte sachets – dispense 10 sachets @ $2.30 x 3% = $2.369 plus per pack fee $0.255 = Total $2.624 compared to
Electral sachets – dispense 10 sachets @ $1.954 x 3% = $2.0126 plus per pack fee pro rata $0.051 = Total $2.0636
All extra margin is important to your business and in this case it is $0.5604 per 10 sachets. Not including repackaging costs.
Due to price category change from Low Cost Medicine to Rebateable product we cannot implement automatic replacement.
You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 April 2020.
Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.
Note: Electral sachet makes 1litre compared to Enerlyte 200ml
ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 April 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.
Together we can make this a seamless and painless transition.
We thank you in anticipation of your ongoing support.